Filing Details
- Accession Number:
- 0001192482-19-000405
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2019-11-13 16:32:40
- Reporting Period:
- 2019-11-08
- Accepted Time:
- 2019-11-13 16:32:40
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1267565 | Collegium Pharmaceutical Inc | COLL | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1640701 | B Alison Fleming | C/O Collegium Pharmaceutical, Inc. 100 Technology Center Drive Stoughton MA 02072 | Chief Technology Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2019-11-08 | 25,000 | $5.73 | 98,556 | No | 4 | M | Direct | |
Common Stock | Disposition | 2019-11-08 | 25,000 | $19.44 | 73,556 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (Right to Purchase) | Disposition | 2019-11-08 | 25,000 | $0.00 | 25,000 | $5.73 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
35,378 | 2025-03-19 | No | 4 | M | Direct |
Footnotes
- The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.10 to $19.71, inclusive. The reporting person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The option was fully vested and exercisable as of November 8, 2019.